Protillion Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Protillion Biosciences's estimated annual revenue is currently $1.4M per year.
- Protillion Biosciences's estimated revenue per employee is $77,500
Employee Data
- Protillion Biosciences has 18 Employees.
- Protillion Biosciences grew their employee count by 157% last year.
Protillion Biosciences's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO, Co-Founder | Reveal Email/Phone |
2 | Co-Founder | Reveal Email/Phone |
3 | Head Software & Bioinformatics | Reveal Email/Phone |
4 | Head Engineering | Reveal Email/Phone |
5 | Head Antibody Engineering | Reveal Email/Phone |
6 | Platform Technology Lead | Reveal Email/Phone |
7 | Lead Systems Engineer | Reveal Email/Phone |
Protillion Biosciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Protillion Biosciences?
Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. We have developed an entirely novel, powerful and high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.
keywords:N/AN/A
Total Funding
18
Number of Employees
$1.4M
Revenue (est)
157%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.6M | 18 | 0% | N/A |
#2 | $2.8M | 18 | 64% | N/A |
#3 | $1.5M | 19 | N/A | N/A |
#4 | $1.7M | 19 | 19% | N/A |
#5 | $2.1M | 21 | -9% | N/A |